Research Article

Effectiveness of GnRH Antagonists and Agonists in Patients with Hormone-Sensitive Prostate Cancer: A Retrospective Study

Zhenghao Liu, Chunguang Yang, Xing Zeng, Chunjin Ke, Jihua Tian, Zhihua Wang, and Zhiquan Hu

Department of Urology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Correspondence should be addressed to Zhiquan Hu; huzhiquan2000@163.com

Received 4 March 2022; Revised 20 April 2022; Accepted 27 April 2022; Published 9 June 2022

Academic Editor: Fahd Abd Algalil

Copyright © 2022 Zhenghao Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To assess the effectiveness of gonadotropin-releasing hormone (GnRH) antagonists and agonists in the treatment of patients with hormone-sensitive prostate cancer (HSPC), thus providing valid data support for their clinical treatment.

Methods. We collected 52 and 65 HSPC patients treated with GnRH antagonists and agonists, respectively, in Tongji Hospital, Tongji Medical College of HUST between May 2019 and April 2021. Prostate-specific antigen (PSA) levels before and after treatment were recorded and analyzed. Further, univariate and multivariate logistic regressions were used to analyze the influencing factors of PSA control rate in HSPC patients. Results. In patients receiving antagonist, the control rate of prostate-specific antigen (PSA) was 54.28% and 88% without and with abiraterone, respectively, and 47.91% and 72% in patients treated using agonist without and with abiraterone. In 32 pairs of patients obtained via propensity score matching, the PSA control rates were 84.38% and 53.13% for those receiving antagonists and agonists, respectively, and 66.67% and 50% for those without abiraterone, respectively. In addition, univariate logistic regression analysis showed that the type of androgen deprivation therapy (ADT) drugs and combined use of abiraterone had a significant effect on the control rate of PSA. Further multivariate logistic regression revealed that GnRH antagonists in ADT drugs were risk factors for PSA control rate.

Conclusion. The PSA control rate of HSPC patients treated with GnRH antagonist is significantly higher than that of the agonist group, and the use of GnRH antagonist is an independent predictor of PSA control rate.

1. Introduction

Prostate cancer (PCa) is the most common nonskin cancer and the second leading cause of cancer-related death in males, with an increasing incidence of approximately 160,000 cases and 366,000 deaths per year [1, 2]. More Chinese prostate cancer patients are diagnosed in the late stage due to low awareness and screening rates [3]. Since the growth of PCa cells is dependent on androgens, androgen deprivation therapy (ADT) is the main treatment for advanced, metastatic, or recurrent PCa [4]. Most patients with metastatic hormone-sensitive prostate cancer (mHSPC) initially respond to ADT [5]. Studies have shown that the 5-year survival rate for metastatic HSPC is only 30% [6]. The purpose of ADT is to inhibit serum testosterone to castration levels, thereby preventing androgen receptor (AR) activation [7]. A significant decrease in prostate-specific antigen (PSA) levels occurs in most patients treated with ADT, and PSA levels may remain low or undetectable for many years, but biochemical recurrences are frequent [8].

Common drugs for ADT include gonadotropin-releasing hormone (GnRH) agonists and antagonists, which can achieve chemical castration on PCa patients [9, 10]. GnRH agonists act by inhibiting the production of luteinizing hormone (LH) and thus the synthesis of testosterone to depot levels without a flare phenomenon [11]. GnRH antagonists prevent rapid and reversible production of LH and FSH, thereby inhibiting testosterone to depot levels without a flare phenomenon [12]. In order to improve the therapeutic efficacy, GnRH agonists are also combined with antiandrogens as a classic mode for PCa treatment. But even if antiandrogens are used in combination to block adrenal-derived androgens, a significant portion of patients will experience testosterone rebound two weeks after GnRH agonist injection, and present with
aggravated symptoms, such as increased bone pain, urinary tract obstruction, and spinal cord compression [13]. And some patients will develop resistance to GnRH agonists [14]. By contrast, degarelix, the new generation of GnRH antagonist, can rapidly inhibit the release of gonadotropins without testosterone rebound and the above clinical symptoms [15, 16]. Previous domestic studies have been limited to GnRH agonists but lack the comparison of the efficacy between antagonists and agonists. Therefore, this study retrospectively collected the clinical data of HSPC patients treated with GnRH antagonists and agonists. Based on collected data, we analyzed and investigated the effectiveness of GnRH antagonists and agonists.

2. Materials and Methods

2.1. Study Subjects. We collected 52 HSPC patients that received GnRH antagonist therapy and 65 HSPC patients that received GnRH agonist therapy at the Department of Urology, Tongji Hospital, Tongji Medical College of HUST between May 2019 and April 2021. All patients were aged over 18 years. Inclusion criteria were as follows: (1) histologically or cytologically confirmed PCa without ADT; and (2) receiving bone scan, chest and abdomen CT, pelvic MRI, and other examinations before starting treatment to determine TNM staging. Exclusion Criteria were as follows: (1) patients with ADT treatment duration of more than 3 months; (2) patients taking other endocrine drugs except abiraterone and apalutamide during treatment; and (3) patients who were not followed up regularly as required during treatment.

General data of patients, such as age, TNM stage, Gleason score, and serum PSA baseline concentration, were recorded. Informed consent was obtained from each patient, and this study was approved by the Ethics Committee of Tongji Hospital, Tongji Medical College of HUST (No. TG-IRB20211246).

2.2. Treatment Methods. Patients in the antagonist group were subcutaneously injected with degarelix at an initial dose of 240 mg and a maintenance dose of 80 mg, and the injection was given every 28 days. Based on this, 23 patients were treated with 1000 mg abiraterone plus 5 mg prednisone additionally.

Patients in the agonist group were treated with subcutaneous injection of 3.75 mg leupreolrelin, subcutaneous injection of 3.6 mg goserelin, or intramuscular injection of 3.75 mg triptorelin. The injection was also given every 28 days. Based on this, 17 patients additionally received 1000 mg abiraterone plus 5 mg prednisone, and the remaining patients were treated with 50 mg oral bicalutamide daily.

2.3. Prostate-Specific Antigen (PSA) Test. Fasting blood was collected from patients after receiving ADT in the morning, allowed to stand at room temperature for 2 h, and centrifuged at 3500 × rpm for 10 min. Subsequently, the supernatant was collected and serum PSA levels were measured using an automatic biochemical analyzer (Mindray, China). The time to examine PSA level after receiving ADT treatment was used as the time for the first reexamination, and the postoperative follow-up examination time was 1.5 years. The PSA control rate (>90%) was defined as a PSA decrease of more than 90% from baseline at the time of reexamination.

2.4. Statistical Analysis. The experimental results were statistically analyzed using SPSS 26.0. Measurement data with normal distribution were expressed as mean ± standard deviation (SD), and T test was used for comparison; measurement data with nonnormal distribution were expressed as median, and Mann–Whitney U test was for analysis. Enumeration data was expressed as percentage (%). Propensity score matching (PSM) was adopted, with a module was used for propensity score matching analysis, with a matching tolerance (caliper width) of 0.02 and matching indicators of age, Gleason score, PSA level, TNM stage, and time to first reexamination. Univariate and multivariate logistic regressions were performed to analyze the factors influencing the PSA control rate in HSPC patients. P < 0.05 was considered to indicate a statistically significant difference.

3. Results

3.1. Comparison of the Efficacy between Two Treatments before PSM. In this study, 52 and 65 patients with HSPC treated with GnRH antagonists and agonists, respectively, were included, with no significant differences in average age (67.24 ± 8.873 years vs. 68.14 ± 7.557 years), TNM stage (T1-T2: 2 vs. 8; T3-T4: 10 vs. 13, M1: 40 vs. 44), Gleason score (score ≤ 7: 15 vs. 18; score > 7: 37 vs. 47), and the median time to reexamination (36 days vs. 38 days). The PSA control rates were 88% and 62% in patients with abiraterone in the antagonist and agonist groups, respectively, and 54.28% and 47.91% in patients without abiraterone in the two groups. The PSA control rate was higher in the antagonist group than in the agonist group (Table 1).

3.2. Comparison of the Efficacy between Two Treatments after PSM. Since there was a significant difference in PSA levels between the two groups, we then used PSM to increase intergroup comparability. A total of 32 pairs of patients were obtained. After PSM, there was no significant difference between the antagonist group and agonist group in the median time to reexamination (60 days vs. 63 days) (Table 2). The PSA control rates of patients with abiraterone were 84.38% and 53.13% in the antagonist group and agonist group, respectively, and 66.67% and 50% in patients without abiraterone in the two groups, respectively. The PSA control rate in the antagonist group was still higher than in the agonist group.

3.3. Factors Affecting PSA Control Rate in HSPC Patients after PSM. We next performed univariate and multivariate logistic regression analyses to determine factors influencing PSA control rate in PCa patients after PSM. The univariate analysis results showed that combined use of abiraterone (P = 0.011) and GnRH agonists (P = 0.011) was significantly associated with the PSA control rate, suggesting that they might be the influencing factors of PSA control rate for HSPC patients. Multivariate logistic regression analysis
of these two factors further showed that GnRH antagonists ($P = 0.044$) had statistical significance, indicating that ADT drugs (antagonists) were independent risk factors in PSA control rate (Table 3).

### 4. Discussion

ADT is the cornerstone for PCa treatment, aiming to rapidly reduce testosterone to castrate levels. The main methods of ADT are surgical castration and medical castration. The drugs used for medical castration are mainly luteinizing hormone-releasing hormone (LHRH) agonists and GnRH antagonists [17]. LHRH acts more slowly, with a high level of testosterone in the first ten days after injection, while GnRH antagonists directly compete with receptors on the pituitary gland and rapidly inhibit the release of gonadotropins without testosterone rebound at the early stage of injection. Moreover, degarelix overcomes the problems of first- and second-generation antagonists, such as short lasting efficacy and the induction of allergic reactions [16, 18, 19], becoming a popular option for medical castration. It has been reported that antagonists can not only achieve the suppression of testosterone secretion through the inhibition of the GnRH receptor, luteinizing hormone secretion and follicle-stimulating hormone secretion, but also significantly reduce the adrenal-derived androgen level in serum [20]. Intermittent treatment with degarelix can maintain the inhibition of PSA and improve sexual function as well as the quality of life [20].

In this study, we found that the PSA control rate in the antagonist group was significantly higher than that in the agonist group, and the control rate in the antagonist plus abiraterone group was higher than that without abiraterone. The above results were consistent with the study by Matsu bara et al. [21]. In order to reduce the evaluation errors, we used PSM to match the baseline data of patients to increase
the comparability between the two groups. After PSM, the PSA control rate of patients in the antagonist group was still significantly higher than that of patients in the agonist group. In addition, logistic regression showed that the type of ADT drugs (antagonists) was an independent risk factor for the PSA control rate. A one-year phase III clinical trial by Sun et al. also indicated that the PSA control rate of patients in the two groups by day 364 was 82.3% and 71.7%, respectively ($P = 0.038$); the antagonist group had significantly better effect, suggesting that degarelix was superior to agonist combined with antiandrogens in PSA control during long-term medical castration therapy [22]. In addition, a comprehensive analysis of multiple clinical trials demonstrated that degarelix maintained PSA at better levels compared to GnRH agonists and also improved lower urinary tract symptoms caused by tumors; the antagonist was also superior to agonists in controlling prostate volume and IPSS score [23–25].

This study still has some limitations, such as small sample size (the best sample size is 42 at a type I error rate of 5% and power of 90%), no record of testosterone and PSA levels 3 days after injection, and no data on testosterone during reexamination. The lack of these data limits the analysis accuracy of short-term efficacy of these two groups. This study is designed to explore the advantages of GnRH antagonist, so clinical studies with more than 1 year of follow-up are more conducive to highlighting the advantages. Finally, there are fewer study indicators. Clinical studies have found safety issues with GnRH agonists and antagonists when performing ADT as well, such as cardiovascular disease, metabolic dysfunction, and fractures [26–28]. These all require further larger sample sizes for comparison.

5. Conclusion

In summary, GnRH antagonists have distinct advantages in PSA control over GnRH agonists. A combination of GnRH antagonists and abiraterone may achieve better results in PSA control rates. Collectively, our study provides an effective theoretical basis for the clinical treatment of HSPC.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

### Table 3: Univariate and multivariate logistic regression analysis.

| Univariate logistic regression analysis | OR  | 95% CI   | P value | Multivariate logistic regression analysis | OR  | 95% CI   | P value |
|----------------------------------------|-----|----------|---------|-----------------------------------------|-----|----------|---------|
| Variables                              |     |          |         |                                         |     |          |         |
| Age                                    | 1.017 | 0.938-1.103 | 0.684   |                                         |     |          |         |
| TNM stage (M1)                         | 0.769 | 0.228-2.592 | 0.672   | Combined use of abiraterone             | 5.079 | 1.282-20.125 | 0.011   |
| Gleason score (G27)                    | 0.917 | 0.503-1.670 | 0.776   | Combined use of abiraterone             | 5.079 | 1.282-20.125 | 0.011   |
| PSA baseline level                     | 2.406 | 0.717-8.074 | 0.149   | Combined use of abiraterone             | 5.079 | 1.282-20.125 | 0.011   |
| Reexamination time                     | 1.007 | 0.995-1.02  | 0.233   | Combined use of abiraterone             | 5.079 | 1.282-20.125 | 0.011   |
| ADT drugs (agonists)                   | 4.375 | 1.320-14.504| 0.011   | Combined use of abiraterone             | 5.079 | 1.282-20.125 | 0.011   |

**Ethical Approval**

This study was approved by the Ethics Committee of Tongji Hospital, Tongji Medical College of HUST (No. TG-IRB20211246).

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**Authors’ Contributions**

Zhenghao Liu and Chunguang Yang contributed equally to this work.

**Acknowledgments**

We thank Dr. Ying Wang of Pfizer medical affairs for scientific support. This work was supported by the National Natural Science Foundation of China (No. 81702989).

**References**

[1] U. Testa, G. Castelli, and E. Pelosi, “Cellular and molecular mechanisms underlying prostate cancer development: therapeutic implications,” *Medicines*, vol. 6, no. 3, p. 82, 2019.

[2] H. Sung, J. Ferlay, R. L. Siegel et al., “Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” *CA: a Cancer Journal for Clinicians*, vol. 71, no. 3, pp. 209–249, 2021.

[3] B. J. Dong, D. L. He, M. Z. Li et al., “Safety consensus on classical endocrine therapy for prostate cancer,” *Journal of Modern Urology*, vol. 23, no. 4, pp. 248–258, 2018.

[4] M. Y. Konoshenko, O. E. Bryzgunova, and P. P. Laktionov, “miRNAs and androgen deprivation therapy for prostate cancer,” *Biochimica Et Biophysica Acta. Reviews on Cancer*, vol. 1876, no. 2, p. 186625, 2021.

[5] C. E. Kyriakopoulos, Y. H. Chen, M. A. Carducci et al., “Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial,” *Journal of Clinical Oncology*, vol. 36, no. 11, pp. 1080–1087, 2018.

[6] S. Damodaran, J. M. Lang, and D. F. Jarrard, “Targeting metastatic hormone sensitive prostate cancer: chemohormonal therapy and new combinatorial approaches,” *The Journal of Urology*, vol. 201, no. 5, pp. 876–885, 2019.
[7] C. J. Ryan and D. J. Tindall, “Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically,” *Journal of Clinical Oncology*, vol. 29, no. 27, pp. 3651–3658, 2011.

[8] T. K. Choueiri, W. Xie, A. V. D’Amico et al., “Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy,” *Cancer*, vol. 115, no. 5, pp. 981–987, 2009.

[9] D. P. Dearnaley, D. R. Saltzstein, J. E. Sylvester et al., “The oral gonadotropin-releasing hormone receptor antagonist relugolix as neoadjuvant/adjuvant androgen deprivation therapy to external beam radiotherapy in patients with localised intermediate-risk prostate cancer: a randomised, open-label, parallel-group phase 2 trial,” *European Urology*, vol. 78, no. 2, pp. 184–192, 2020.

[10] O. O. Oduwole, A. Poliandri, A. Okolo et al., “Follicle-stimulating hormone promotes growth of human prostate cancer cell line-derived tumor xenografts,” *The FASEB Journal*, vol. 35, no. 4, p. e21464, 2021.

[11] R. Raj, G. Elshimy, A. Jacob et al., “Pituitary apoplexy induced by gonadotropin-releasing hormone (GnRH) agonist administration for treatment of prostate cancer: a systematic review,” *Journal of Cancer Research and Clinical Oncology*, vol. 147, no. 8, pp. 2337–2347, 2021.

[12] M. Moussa, A. Papatsoris, A. Dellis, M. A. Chakra, and C. Fragkoulis, "Current and emerging gonadotropin-releasing hormone (GnRH) antagonists for the treatment of prostate cancer," *Expert Opinion on Pharmacotherapy*, vol. 22, no. 17, pp. 2373–2381, 2021.

[13] L. Klotz, L. Boccon-Gibod, N. D. Shore et al., “The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer,” *BJU International*, vol. 102, no. 11, pp. 1531–1538, 2008.

[14] T. Ezaki, T. Kosaka, R. Mizuno et al., “Efficacy of treatment with a GnRH antagonist in prostate cancer patients previously treated with a GnRH agonist,” *Cancer Chemotherapy and Pharmacology*, vol. 76, no. 2, pp. 301–306, 2015.

[15] F. Zengerling, J. J. Jakob, S. Schmidt, J. J. Kunath, and F. Meerpohl, "Degarelix for treating advanced hormone-sensitive prostate cancer," *Cochrane Database of Systematic Reviews*, vol. 8, no. 8, 2021.

[16] K. Miller, G. Simson, S. Goble, and B. E. Persson, "Efficacy of degarelix in prostate cancer patients following failure on luteinizing hormone-releasing hormone agonist treatment: results from an open-label, multicentre, uncontrolled, phase II trial (CS27)," *Therapeutic Advances in Urology*, vol. 7, no. 3, pp. 105–115, 2015.

[17] L. Boccon-Gibod, P. Albers, J. Morote et al., "Degarelix as an intermittent androgen deprivation therapy for one or more treatment cycles in patients with prostate cancer," *European Urology*, vol. 66, no. 4, pp. 655–663, 2014.

[18] N. D. Shore, P. A. Abrahamsson, J. Anderson, E. D. Crawford, and P. Lange, "New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists," *Prostate Cancer and Prostatic Diseases*, vol. 16, no. 1, pp. 7–15, 2013.

[19] F. Debruyne, G. Bhat, and M. B. Garnick, "Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer," *Future Oncology*, vol. 2, no. 6, pp. 677–696, 2006.

[20] Y. Miyazawa, Y. Sekine, T. Kyutaka et al., "A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients," *BMC Urology*, vol. 17, no. 1, p. 70, 2017.

[21] N. Matsubara, K. N. Chi, M. Özgüroğlu et al., "Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebo added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study,” *European Urology*, vol. 77, no. 4, pp. 494–500, 2020.

[22] Y. Sun, L. Xie, T. Xu et al., "Efficacy and safety of degarelix in patients with prostate cancer: results from a phase III study in China,” *Asian Journal of Urology*, vol. 7, no. 3, pp. 301–308, 2020.

[23] P. C. Albertsen, L. Klotz, B. Tombal, J. Grady, T. K. Olesen, and J. Nilsson, "Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist,” *European Urology*, vol. 65, no. 3, pp. 565–573, 2014.

[24] G. Geiges, T. Harms, G. Rodemer et al., "Degarelix therapy for prostate cancer in a real-world setting: experience from the German IQUO (Association for Uro-Oncological Quality Assurance) Firmagon® registry,” *BMC Urology*, vol. 15, no. 1, p. 122, 2015.

[25] K. Axcrorna, S. Aaltomaa, C. M. da Silva et al., "Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide,” *BJU International*, vol. 110, no. 11, pp. 1721–1728, 2012.

[26] S. J. Freedland and P. A. Abrahamsson, "Androgen deprivation therapy and side effects: are GnRH antagonists safer?,” *Asian Journal of Andrology*, vol. 23, no. 1, pp. 3–10, 2021.

[27] C. Jin, Y. Fan, Y. Meng et al., "A meta-analysis of cardiovascular events in intermittent androgen- deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients,” *Prostate Cancer and Prostatic Diseases*, vol. 19, no. 4, pp. 333–339, 2016.

[28] K. Mitsuzuka, A. Kyan, T. Sato et al., "Influence of 1 year of androgen deprivation therapy on lipid and glucose metabolism and fat accumulation in Japanese patients with prostate cancer,” *Prostate Cancer and Prostatic Diseases*, vol. 19, no. 1, pp. 57–62, 2016.